Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 3/20 | 0.50 |
| ▸ | HTR2B | P41595 | 3/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30561524 | 1.00 | PNMT (0.56) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL1953206 | 0.87 | DRD2 (0.59) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL29507804 | 0.87 | DRD2 (0.59) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL1950952 | 0.87 | DRD2 (0.51) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL14878929 | 0.86 | PNMT (0.55) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL8667965 | 0.85 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL7764313 | 0.85 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL12004879 | 0.84 | PNMT (0.56) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL9716410 | 0.82 | PNMT (0.48) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL14875742 | 0.81 | PNMT (0.46) | PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661918-B1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | RECURIUM IP HOLDINGS LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-109810111-B | Pyrazolopyrimidine compound, and preparation method and application thereof | 上海医药集团股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-111094253-B | 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one analogs | 里科瑞尔姆IP控股有限责任公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2022174796-A1 | PYRIMIDINE COMPOUND AS WEE-1 INHIBITOR | 微境生物医药科技(上海)有限公司 | 2022-08-25 | — | — | WO | disclosed |
| US-20210317124-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | RECURIUM IP HOLDINGS, LLC | 2021-10-14 | — | — | US | disclosed |
| US-11124518-B2 | L,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-one analogs | RECURIUM IP HOLDINGS, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3661918-A1 | 1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D]PYRIMIDIN -3 - ONE ANALOGS | Recurium IP Holdings, LLC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20200157112-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | RECURIUM IP HOLDINGS, LLC | 2020-05-21 | — | — | US | disclosed |
| CN-111094253-A | 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one analogs | 里科瑞尔姆IP控股有限责任公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2019028008-A1 | 1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D] PYRIMIDIN -3 - ONE ANALOGS | Zeno Royalties & Milestones, LLC (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-1971606-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20080090887-A1 | Heat Shock Protein 90 (HSP90); treating cancer, inflammatory disorders, angiogenesis inhibition, infections; 3-substituted-4-fused(hetero)aryl-5-phenyl-4H-1,2,4-triazoles | SYNTA PHARMACEUTICALS CORP. | 2008-04-17 | — | — | US | disclosed |
| US-20080090887-A1 | Heat Shock Protein 90 (HSP90); treating cancer, inflammatory disorders, angiogenesis inhibition, infections; 3-substituted-4-fused(hetero)aryl-5-phenyl-4H-1,2,4-triazoles | SYNTA PHARMACEUTICALS CORP. | 2008-04-17 | — | — | US | disclosed |
| US-20080090887-A1 | Heat Shock Protein 90 (HSP90); treating cancer, inflammatory disorders, angiogenesis inhibition, infections; 3-substituted-4-fused(hetero)aryl-5-phenyl-4H-1,2,4-triazoles | SYNTA PHARMACEUTICALS CORP. | 2008-04-17 | — | — | US | disclosed |
| US-20080051395-A1 | 2-Pyrimidinyl Pyrazolopyridine Erbb Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051395-A1 | 2-Pyrimidinyl Pyrazolopyridine Erbb Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-02-28 | — | — | US | disclosed |
| WO-2007139955-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139955-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007067506-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007067506-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090887-A1 | Heat Shock Protein 90 (HSP90); treating cancer, inflammatory disorders, angiogenesis inhibition, infections; 3-substituted-4-fused(hetero)aryl-5-phenyl-4H-1,2,4-triazoles | HSP90AB1, HSP90AA1, HSP90AB2P | PNMT 4785/4885ADRA2A 3439/4885ADRA2B 3517/4885 |
| US-20200157112-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | MKI67, BRCA1, CDK4 | PNMT 4734/4885ADRA2A 2905/4885ADRA2B 2405/4885 |
| US-20210317124-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | MKI67, BRCA1, CDK4 | PNMT 4734/4885ADRA2A 2905/4885ADRA2B 2405/4885 |
| US-11124518-B2 | L,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-one analogs | MKI67, BRCA1, CCND1 | PNMT 4761/4885ADRA2A 2730/4885ADRA2B 2261/4885 |
| US-20080051395-A1 | 2-Pyrimidinyl Pyrazolopyridine Erbb Kinase Inhibitors | ERBB2, ERBB3, ERBB4 | PNMT 4181/4885ADRA2A 2918/4885ADRA2B 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.